PentaBase will in collaboration with Istituto Cantonale di Patologia, Switzerland, and the Danish Technological Institute, Denmark, develop a new and improved method for selecting the most efficient treatment and monitor tumor progression in glioma patients.
Gliomas are the most common and lethal of all brain tumors. The disease includes multiple subtypes and grades with varying prognosis and treatment responses. Approximately 78,000 new cases of primary brain tumors were diagnosed globally in 2017, with approximately 25,000 found to be malignant. Today, molecular typing involves several different tedious technologies.
The aim of our project is to improve the care of glioma patients and reduce time and money spent on the diagnosis of these patients. As research into precision medicine continues, patients as well as healthcare professionals are anticipating advancement in the treatment of brain tumors. Healthcare facilities, that are already focused on precision medicine-based treatments, are quickly setting the standard by which other treatment centers will be measured.
To ensure the efficient, sensitive and inexpensive stratification of brain tumors we are going to combine four different genetic analyses into a single platform technology, working on open, real-time PCR instruments. Furthermore, we will try to develop a sensitive method for monitoring glioma progression based on liquid biopsies like blood samples and/or cerebral spinal fluids.
SensiScreen Glioma is a three-year project supported by EU, Denmark and Switzerland through the EuroStars program. We invite stakeholders with interests in this field to contact us at email@example.com for questions, potential participation or input to the project. Alternatively, you can visit us at Medica on November 12-16. 2018, Düsseldorf, Hall Booth F53.